Five years into the PRISM-LT project, a European research team is moving toward commercial applications of 3D-printed living tissue. But existing EU regulatory frameworks weren’t designed for what they’re building. Funded by the European Union and scheduled to end in 2027, the project is developing engineered living materials that combine living cells with genetically modified microorganisms. Neither conventional medicine rules nor food regulations fit the technology neatly. That mismatch will shape whether European biotech capitalizes on the innovation or watches rivals in the US and Asia move faster.
Massimo Vassalli, the project’s scientific coordinator and chair of bioengineering at the University of Glasgow, describes the core innovation plainly: the team prints tissues from capsules containing living cells and bioink, then positions them layer by layer with a robotic arm. Unlike continuous-flow printing methods, each capsule holds a scaffold and genetically modified microorganisms—typically yeast or bacteria—that detect when stem cells begin to differentiate and release chemical signals to steer them toward desired tissue types. Manufacturing takes from a few minutes to an hour. Maturation takes about three weeks, as stem cells develop into bone, fat, or muscle.
The team can now produce roughly one square centimeter of thin tissue and is working toward one cubic centimeter. Two applications come first: bone marrow models for drug testing in leukemia research, and muscle-and-fat structures for cultivated meat that reproduce the texture and marbling consumers expect from conventional meat. Laura Martinelli, PRISM-LT project coordinator and executive director of In Society, a research organization based in Udine, Italy, was direct about the commercial stakes: “Thanks to our bioprinting technology, we can achieve the right texture in alternative meats, which gives us the opportunity to commercialize them.”
The Regulatory Maze
Here’s where European competitiveness hits a wall. Engineered living materials—composites wholly or partly made of living cells, including genetically modified microorganisms—don’t fit existing EU frameworks. They aren’t medicines under the European Medicines Agency’s definition, because they don’t treat disease. They aren’t conventional food, because they contain lab-grown tissue and genetically modified organisms. And they aren’t industrial biomaterials, because they’re alive and self-repair.
Martinelli acknowledged the bind: “We have to adopt a new attitude toward this technology.” The team is working with the European Innovation Council and has contacted the European Medicines Agency and other regulatory authorities to examine future rules and authorizations. That’s the diplomatic version of saying the rules don’t exist yet, and Europe is playing catch-up.
This is precisely where EU regulatory timidity becomes a competitive liability. When faced with novel biotechnology, the bloc’s instinct is precaution: slow approval, heavy documentation, long review cycles. That approach has merit when safety is genuinely uncertain. But cultivated meat, bone marrow models for drug testing, and organ-on-a-chip platforms for personalized medicine aren’t speculative; they’re commercially viable within years, not decades. The question is whether European companies will reach the market first or whether regulatory delay will cede the field to American and Asian competitors with faster approval pathways.
Scaling as the Next Frontier
Vassalli said engineered living materials could be “extremely powerful” if widely applied, but scaling remains the binding constraint. “When we launched the project, we asked two key questions: is it viable? and is it scalable? Now we can say it is viable.” Scaling up comes next. Moving from one cubic centimeter to industrial production will require robotics, quality control, and regulatory certainty—none of which Europe has yet provided.
The technology’s complexity shows why regulatory frameworks matter. The team had to engineer a symbiosis between systems that don’t naturally coexist. “We have to create a symbiotic relationship between two systems not designed to live together, like yeast and stem cells,” Vassalli explained. “The main challenge is to create conditions suitable enough for both the yeast or bacteria and the stem cells while the latter differentiate.” For cultivated meat, the researchers chose yeast over bacteria because “It would be hard to explain to consumers that meat was made using bacteria.” The choice reflects a commercial reality: regulators and consumers will demand transparency about what’s living inside the tissue.
Martinelli was cautious about timelines: “We are still far from real-world applications. We focus on principles and mechanisms to see what is viable. However, we are already considering future challenges.” Her circumspection is warranted, but it also highlights the gap. European researchers lead in fundamental innovation by years. Without a regulatory pathway that moves faster than it does now, that scientific lead won’t translate into commercial or industrial dominance.
Why This Matters:
Bioprinting and engineered living materials mark a frontier where European science is genuinely world-leading. But leadership in the lab doesn’t guarantee leadership in the marketplace, and Europe has a poor track record of turning basic research into scalable industrial applications. The PRISM-LT project’s success depends less on further scientific breakthroughs than on regulatory authorities acting decisively to clear a pathway for approval. The European Medicines Agency and member-state food authorities must develop frameworks that recognize genuine safety concerns while avoiding the precautionary paralysis that has ceded other biotech sectors to American and Chinese competitors. If Europe delays while regulators elsewhere green-light cultivated meat, bone marrow models, and organ-on-chip platforms, the innovation will have happened here, but the industry will grow elsewhere. That’s not a scientific failure—it’s a policy one.